Pervin Korkmaz Ekren

Pervin Korkmaz Ekren

Auto-generated profile, based on publicly available information

Pervin Korkmaz Ekren

Department of Chest Diseases, Faculty of Medicine, Ege University, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

23 September 2018 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
PEPervin Korkmaz Ekren
Pervin Korkmaz Ekren
ZTZehra Toreyin
Zehra Toreyin
PNPayam Nahid
Payam Nahid
MDMert Doskaya
Mert Doskaya
ACAyse Caner
Ayse Caner
SESelda Erensoy
Selda Erensoy

31 May 2016 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
PEPervin Korkmaz Ekren
Pervin Korkmaz Ekren
BABurcu Basarik Aydogan
Burcu Basarik Aydogan
AGAlev Gurgun
Alev Gurgun
MTMehmet Sezai Tasbakan
Mehmet Sezai Tasbakan
FBFeza Bacakoglu
Feza Bacakoglu
SNStefano Nava
Stefano Nava
Noninvasive ventilation (NIV) is a cornerstone for the treatment of acute respiratory failure of various etiologies. Using NIV is discussed in mild-to-moderate acute respiratory distress syndrome (ARDS) patients (PaO2/FiO2 > 150). These patients often have comorbidities that increase the risk for bronchoscopy related complications. The primary outcome of this prospective observational study was to evaluate the feasibility, safety and contribution in diagnosis and/or modification of the ongoing treatment of fiberoptic bronchoscopy (FOB) in patients with ARDS treated with NIV. ARDS patients treated with NIV and who require FOB as the diagnostic or therapeutic procedure were included the study. Intensive care ventilators or other dedicated NIV ventilators were used. NIV was applied via simple oro-nasal mask or full-face mask. Pressure support or inspiratory positive airway pressure (IPAP), external positive end expiratory pressure (PEEP) or expiratory positive airway pressure (EPAP) levels were titrated to achieve an expiratory tidal volume of 8 to 10 ml/kg according to ideal body weight, SpO2 > 90 % and respiratory rate below 25/min. Twenty eight subjects (mean age 63.3 ± 15.9 years, 15 men, 13 women, PaO2/FiO2 rate 145 ± 50.1 at admission) were included the study. Overall the procedure was well tolerated with only 5 (17.9 %) patients showing minor complications. There was no impairment in arterial blood gas and cardiopulmonary parameters after FOB. PaO2/FiO2 rate increased from 132.2 ± 49.8 to 172.9 ± 63.2 (p = 0.001). No patient was intubated within 2 h after the bronchoscopy. 10.7, 32.1 and 39.3 % of the patients required invasive mechanical ventilation after 8 h, 24 h and 48 h, respectively. Bronchoscopy provided diagnosis in 27 (96.4 %) patients. Appropriate treatment was decided according to the results of the bronchoscopic sampling in 20 (71.4 %) patients. FOB under NIV could be considered as a feasible tool for diagnosis and guide for treatment of patients with ARDS treated via NIV in intensive care units. However, FOB-correlated life-treathening complications in severe hypoxemia should not be forgotten. Furthermore, further controlled studies involving a larger series of homogeneous ARDS patients undergoing FOB under NIV are needed to confirm these preliminary findings.

28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
HEHüseyi̇n Aytaç Erdem
Hüseyi̇n Aytaç Erdem
PEPervİn Korkmaz Ekren
Pervİn Korkmaz Ekren
DÇDerya Çağlayan
Derya Çağlayan
MTMeltem Taşbakan
Meltem Taşbakan
TYTansu Yamazhan
Tansu Yamazhan
DGDeniz Gokengin
Deniz Gokengin
The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS CoV-2 pneumonia. This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the ICU when this paper was written. This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.

1 January 2015 in Turkish Journal of Pathology
Verified
Journal Article
Open access
BYBanu Yaman
Banu Yaman
DNDeniz Nart
Deniz Nart
PEPervin Korkmaz Ekren
Pervin Korkmaz Ekren
GCGursel Cok
Gursel Cok
AVAli Veral
Ali Veral
Lung cancer is still the leading cause of cancer mortality. Antiapoptotic genes and protease inhibitors play an important role in the development of lung cancer. p63, TTF-1 and maspin expression and their role in the differential diagnosis, overall survival, progression-free survival and other clinicopathological characteristics of the patients were investigated in 80 surgically-resected non-small cell lung carcinomas. The maximal tumor diameter range was 1.5-11 cm (mean: 4.06±1.8 cm). Forty-five (56.3%) tumors were adenocarcinoma, 23 (28.8%) squamous cell carcinoma, four (5%) large cell carcinoma, six (7.5%) large cell neuroendocrine carcinoma, one (1.2%) sarcomatoid carcinoma while one was (1.2%) both adenocarcinoma and squamous cell carcinoma. The patients with advanced TNM stage and a tumor diameter more than 3 cm had markedly poor survival. Immunohistochemically, p63 staining was present in 87.5% of squamous cell carcinomas, 4.3% of adenocarcinomas, 25% of large cell carcinomas, and 16.7% of large cell neuroendocrine carcinomas. Similarly, maspin was positive in 66.7% of squamous cell carcinomas and 17.4% of adenocarcinomas. The TTF-1 staining rate was higher in adenocarcinomas (84.8%). There was no immunoreactivity in squamous cell carcinomas (p < 0.001). We found that p63 and TTF-1 had no significant effect on survival in either tumor group (p > 0.05) while maspin has a negative prognostic effect in adenocarcinoma (p=0.048). This study suggests that p63 and TTF-1 are reliable markers in non-small cell lung carcinoma and can be used in differential diagnosis. Maspin has been identified as a prognostic marker in adenocarcinoma. However, more studies are required to elucidate the significance of maspin.

20 December 2013 in Tuberk Toraks
Verified
Journal Article
Closed access
AGAlev Gürgün
Alev Gürgün
PEPervin Korkmaz Ekren
Pervin Korkmaz Ekren
FBFeza Bacakoğlu
Feza Bacakoğlu
ÖBÖzen Kaçmaz Başoğlu
Özen Kaçmaz Başoğlu
NDNigar Di̇ri̇can
Nigar Di̇ri̇can
ASAbdullah Sayiner
Abdullah Sayiner
Ventilator associated pneumonia (VAP) is one of the most important causes of mortality in patients treated with invasive mechanical ventilation (IMV) in intensive care unit (ICU). Microbiological examinations are required as clinical and radiological findings are usually insufficient in the diagnosis.